Actionable news
0
All posts from Actionable news
Actionable news in DYAX: Dyax Corp.,

Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited

In a recent filing with the Securities and Exchange Commission (SEC), James E. Flynn (pictured) has revealed his latest play: Akari Therapeutics PLC (ADR) (NASDAQ:AKTX), a clinical-stage biopharmaceutical company formerly known as Celsus Therapeutics PLC. Flynn’s Deerfield Management has built a position that amasses 115.0 million shares, which account for 9.77% of the company’s common stock. According to a separate filing with the SEC, Robert Polak, the manager of Anchor Bolt Capital, has reignited his interest in Hornbeck Offshore Services, Inc. (NYSE:HOS), a provider of equipment and services for oil drilling companies. Having previously reduced his stake in the company, Polak has doubled the position reported in Anchor’s latest 13F filing, taking it to 2.3 million shares or 6.42% of the company’s outstanding shares.

James Flynn Deerfield Management

Founded in 1994, Deerfield Management invests mainly in healthcare stocks and administers four hedge funds with a total of $5 billion in assets under management. James Flynn took the helm in 2000 and has built an equity portfolio with an estimated market value of $3 billion at the end of the second quarter. At the end of July, Deerfield announced the launch of Deerfield Healthcare Innovations Fund, which will focus on innovative treatments for genetic disorders and cancer. According to Deerfield’s latest 13F filing, Flynn’s largest equity bet is Horizon Pharma PLC (NASDAQ:HZNP), despite being trimmed by 5% to 12.2 million shares during the quarter. Flynn’s interest in Dyax Corp. (NASDAQ:DYAX) also intensified, as he boosted his stake by 120% to amass 2.48 million shares, while his investment in Flamel Technologies S.A. (ADR) (NASDAQ:FLML), his second-biggest equity position, was left...


More